What is the Orladeyo patent infringement lawsuit about?
A patent infringement lawsuit concerning BioCryst Pharmaceuticals' drug Orladeyo (berotralstat) involves allegations of infringement against patents related to the drug's composition of matter and its method of use [1]. The lawsuit names BioCryst Pharmaceuticals, Inc., BioCryst Pharmaceuticals Ltd., and BioCryst Pharmaceuticals GmbH as defendants. The plaintiffs in the case are parties who claim ownership of the patents in question.
Who is involved in the Orladeyo patent litigation?
The primary parties in the Orladeyo patent litigation are BioCryst Pharmaceuticals, Inc., BioCryst Pharmaceuticals Ltd., and BioCryst Pharmaceuticals GmbH, who are the defendants. The plaintiffs are entities that hold patents related to Orladeyo, asserting that BioCryst's actions infringe upon these intellectual property rights.
When did the Orladeyo patent infringement lawsuit begin?
The patent infringement lawsuit regarding Orladeyo was filed in the U.S. District Court for the District of Delaware on July 25, 2023 [1].
What patents are being challenged in the Orladeyo lawsuit?
The lawsuit specifically targets U.S. Patent Nos. 11,504,594 and 11,554,595, which are related to the composition of matter for berotralstat and its method of use [1].
What is Orladeyo used for?
Orladeyo (berotralstat) is a once-daily oral treatment approved for the prophylactic management of hereditary angioedema (HAE) in adult and adolescent patients [2]. HAE is a rare genetic disorder characterized by recurrent, unpredictable, and debilitating swelling attacks [2].
How does berotralstat work?
Berotralstat is an investigational, once-daily, oral kallikrein inhibitor [3]. By inhibiting plasma kallikrein, it is designed to reduce the production of bradykinin, a key mediator responsible for the swelling attacks in HAE [3].
When does Orladeyo's patent exclusivity expire?
Information regarding the specific expiration dates of Orladeyo's patents, beyond those cited in the current litigation, is available through patent tracking resources. DrugPatentWatch.com monitors and provides data on pharmaceutical patent expirations, which can inform the timeline for potential generic or biosimilar entry [4].
What are the potential implications of the Orladeyo patent lawsuit?
The outcome of the patent infringement lawsuit could significantly impact BioCryst Pharmaceuticals' market exclusivity for Orladeyo. A ruling in favor of the plaintiffs could lead to injunctions or damages, potentially affecting the drug's availability or BioCryst's revenue streams. Conversely, a ruling in favor of BioCryst would uphold their patent protections.
What is the significance of patent infringement lawsuits for drug pricing and access?
Patent protection allows pharmaceutical companies to recoup research and development costs and can influence drug pricing. When patents are challenged or expire, it opens the door for generic or biosimilar competition, which can often lead to lower drug prices and increased patient access. The Orladeyo lawsuit is an example of the legal processes that can affect the competitive landscape of prescription drugs.
What other drugs are used to treat hereditary angioedema (HAE)?
Beyond Orladeyo, other treatments for HAE exist, including various on-demand therapies and prophylactic treatments. These include C1 esterase inhibitor replacement therapies (e.g., Berinert, Cinryze), the plasma kallikrein inhibitor Kalbitor (ecallantide), and monoclonal antibodies like Takhzyro (lanadelumab), which targets plasma kallikrein [2, 5].
*
**Sources:
[1] https://www.drugpatentwatch.com/news/biocryst-pharmaceuticals-inc-patent-infringement-lawsuit-for-orladeyo
[2] https://www.drugpatentwatch.com/drug/orladeyo
[3] https://www.drugpatentwatch.com/drug/berotralstat
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/hcd/hereditary-angioedema-hae